USMLE Step 3 Quiz: Chronic Kidney Disease Management

What this quiz covers

This quiz focuses on Chronic Kidney Disease Management, giving you a quick way to practice the rules, question types, and explanations that matter most for USMLE Step 3.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Nephrology for renal replacement therapy education and planning (correct answer)
2. Cardiology for routine stress testing before dialysis
3. Gastroenterology for endoscopy to evaluate nausea
4. Urology for cystoscopy to evaluate CKD progression

Explanation: This question tests chronic kidney disease management skills, specifically focusing on evidence-based referral timing for renal replacement therapy in advanced CKD patients. Chronic kidney disease management involves regular monitoring of renal function, adjusting medications based on kidney status, and managing complications like anemia and electrolyte imbalances. In the presented vignette, the patient's eGFR of 9 and uremic symptoms indicate the need for predialysis education and planning. The correct choice, nephrology for renal replacement therapy education and planning, accurately reflects current guidelines for managing CKD stage 5, demonstrating the student's understanding of appropriate clinical interventions. A common distractor may suggest cardiology for stress testing, which is not routinely required, highlighting a frequent misconception. To improve understanding, students should focus on guidelines for dialysis initiation, regularly review eGFR trends, and practice identifying indications for specialist referral.

Question 2

1. Initiate oral sodium bicarbonate supplementation. (correct answer)
2. Encourage a diet high in protein to improve muscle strength.
3. Administer a bolus of intravenous normal saline.
4. Advise an increased intake of citrus fruits and juices.

Explanation: The patient has metabolic acidosis, a common complication of advanced CKD. Guidelines recommend treating metabolic acidosis with oral alkali supplementation (e.g., sodium bicarbonate) when the serum bicarbonate level is persistently below 22 mEq/L. Treatment can slow the progression of CKD, improve nutritional status, and alleviate symptoms like fatigue.

Question 3

1. Administer high-dose ibuprofen.
2. Perform urgent pericardiocentesis.
3. Initiate urgent hemodialysis. (correct answer)
4. Administer colchicine and corticosteroids.

Explanation: The clinical presentation of pleuritic chest pain, a pericardial friction rub, and diffuse ST elevations in a patient with end-stage renal disease who has missed dialysis is classic for uremic pericarditis. This is an absolute and urgent indication for the initiation of renal replacement therapy. The definitive treatment is hemodialysis to remove the uremic toxins causing the inflammation. Pericardiocentesis is only indicated for tamponade.

Question 4

1. Discontinue glyburide and use glipizide instead (correct answer)
2. Increase glyburide dose to overcome insulin resistance
3. Increase metformin dose despite reduced eGFR
4. Stop lisinopril to prevent hypoglycemia episodes

Explanation: This question tests chronic kidney disease management skills, specifically focusing on evidence-based adjustments for hypoglycemic agents in CKD patients. Chronic kidney disease management involves regular monitoring of renal function, adjusting medications based on kidney status, and managing complications like anemia and electrolyte imbalances. In the presented vignette, the patient's hypoglycemia episodes and use of long-acting sulfonylurea indicate the need to switch to a shorter-acting agent. The correct choice, discontinuing glyburide and using glipizide instead, accurately reflects current guidelines for managing diabetes in CKD stage 3b, demonstrating the student's understanding of appropriate clinical interventions. A common distractor may suggest increasing glyburide, which worsens hypoglycemia risk, highlighting a frequent misconception. To improve understanding, students should focus on guidelines for antidiabetic therapy in CKD, regularly review medication clearance, and practice recognizing drug-related adverse events.

Question 5

1. Add patiromer while continuing lisinopril therapy (correct answer)
2. Increase tacrolimus dose to improve graft perfusion
3. Stop mycophenolate to correct hyperkalemia promptly
4. Start spironolactone to lower potassium level

Explanation: This question tests chronic kidney disease management skills, specifically focusing on evidence-based management of hyperkalemia in post-transplant patients. Chronic kidney disease management involves regular monitoring of renal function, adjusting medications based on kidney status, and managing complications like anemia and electrolyte imbalances. In the presented vignette, the patient's hyperkalemia with RAAS inhibition indicates the need for a binder to preserve antiproteinuric therapy. The correct choice, adding patiromer while continuing lisinopril therapy, accurately reflects current guidelines for managing post-transplant CKD, demonstrating the student's understanding of appropriate clinical interventions. A common distractor may suggest stopping mycophenolate, which is unrelated to hyperkalemia, highlighting a frequent misconception. To improve understanding, students should focus on guidelines for electrolyte management post-transplant, regularly review drug interactions, and practice optimizing immunosuppression with comorbidities.

Question 6

1. Secondary hyperparathyroidism with renal osteodystrophy (correct answer)
2. Acute uric acid nephropathy from tumor lysis
3. Postrenal obstruction from benign prostatic hypertrophy
4. Rapidly progressive glomerulonephritis with crescents

Explanation: This question tests chronic kidney disease management skills, specifically focusing on identifying risks for mineral bone disorder complications in CKD patients. Chronic kidney disease management involves regular monitoring of renal function, adjusting medications based on kidney status, and managing complications like anemia and electrolyte imbalances. In the presented vignette, the patient's elevated PTH and hyperphosphatemia indicate secondary hyperparathyroidism, increasing risk for bone disease. The correct choice, secondary hyperparathyroidism with renal osteodystrophy, accurately reflects current guidelines for recognizing CKD-MBD risks in stage 4, demonstrating the student's understanding of appropriate clinical interventions. A common distractor may suggest rapidly progressive GN, which is unlikely without acute changes, highlighting a frequent misconception. To improve understanding, students should focus on guidelines for CKD complications, regularly review PTH and phosphate levels, and practice predicting long-term risks in renal patients.

Question 7

1. Recommend acetaminophen and topical NSAID as needed (correct answer)
2. Start daily oral naproxen for long-term control
3. Start indomethacin because it is kidney-sparing
4. Avoid all analgesics to prevent CKD progression

Explanation: This question tests chronic kidney disease management skills, specifically focusing on evidence-based analgesic selection in CKD patients with osteoarthritis. Chronic kidney disease management involves regular monitoring of renal function, adjusting medications based on kidney status, and managing complications like anemia and electrolyte imbalances. In the presented vignette, the patient's chronic pain and CKD indicate the need for kidney-safe options like acetaminophen and limited topical NSAIDs. The correct choice, recommending acetaminophen and topical NSAID as needed, accurately reflects current guidelines for managing pain in CKD stage 3b, demonstrating the student's understanding of appropriate clinical interventions. A common distractor may suggest daily oral naproxen, which risks worsening renal function, highlighting a frequent misconception. To improve understanding, students should focus on guidelines for analgesia in CKD, regularly review nephrotoxic agents, and practice balancing pain control with renal safety.

Question 8

1. Vascular surgery for arteriovenous fistula evaluation (correct answer)
2. Pulmonology for baseline pulmonary function testing
3. Neurology for screening electroencephalography evaluation
4. Orthopedics for prophylactic fracture risk assessment

Explanation: This question tests chronic kidney disease management skills, specifically focusing on evidence-based referral for vascular access in predialysis CKD patients. Chronic kidney disease management involves regular monitoring of renal function, adjusting medications based on kidney status, and managing complications like anemia and electrolyte imbalances. In the presented vignette, the patient's eGFR of 7 and uremic symptoms indicate imminent need for dialysis, requiring access planning. The correct choice, vascular surgery for arteriovenous fistula evaluation, accurately reflects current guidelines for managing CKD stage 5, demonstrating the student's understanding of appropriate clinical interventions. A common distractor may suggest pulmonology for PFTs, which is not routinely needed, highlighting a frequent misconception. To improve understanding, students should focus on guidelines for dialysis preparation, regularly review access options, and practice timing referrals for advanced CKD.

Question 9

1. Add finerenone for persistent albuminuria (correct answer)
2. Stop empagliflozin due to CKD progression risk
3. Switch lisinopril to hydrochlorothiazide for proteinuria
4. Start high-protein diet to prevent sarcopenia

Explanation: This question tests chronic kidney disease management skills, specifically focusing on evidence-based treatment strategies for persistent albuminuria in diabetic CKD patients. Chronic kidney disease management involves regular monitoring of renal function, adjusting medications based on kidney status, and managing complications like anemia and electrolyte imbalances. In the presented vignette, the patient's high albumin-to-creatinine ratio despite SGLT2 and ACE inhibition indicates the need for additional antiproteinuric therapy. The correct choice, adding finerenone for persistent albuminuria, accurately reflects current guidelines for managing CKD stage 3a in diabetes, demonstrating the student's understanding of appropriate clinical interventions. A common distractor may suggest stopping empagliflozin, which is contraindicated as it provides cardiorenal protection, highlighting a frequent misconception. To improve understanding, students should focus on guidelines for proteinuria management in CKD, regularly review emerging therapies like mineralocorticoid antagonists, and practice interpreting urine albumin levels in diabetic patients.

Question 10

1. Initiate dietary phosphate restriction and phosphate binder (correct answer)
2. Start high-dose calcium supplements without monitoring
3. Begin immediate dialysis for elevated phosphate level
4. Stop losartan to reduce PTH secretion

Explanation: This question tests chronic kidney disease management skills, specifically focusing on evidence-based interventions for mineral bone disorder in CKD patients. Chronic kidney disease management involves regular monitoring of renal function, adjusting medications based on kidney status, and managing complications like anemia and electrolyte imbalances. In the presented vignette, the patient's hyperphosphatemia and elevated PTH indicate the need for phosphate control to prevent further complications. The correct choice, initiating dietary phosphate restriction and phosphate binder, accurately reflects current guidelines for managing CKD stage 4, demonstrating the student's understanding of appropriate clinical interventions. A common distractor may suggest immediate dialysis, which is premature without uremic symptoms, highlighting a frequent misconception. To improve understanding, students should focus on guidelines for phosphate management, regularly review CKD-MBD labs, and practice stepwise approaches to bone-mineral disorders.

Question 11

1. Switch calcium carbonate to sevelamer with meals (correct answer)
2. Add calcitriol as first-line phosphate binder
3. Stop furosemide to reduce phosphate retention
4. Increase dietary phosphate intake to correct pruritus

Explanation: This question tests chronic kidney disease management skills, specifically focusing on evidence-based phosphate binder selection in CKD patients. Chronic kidney disease management involves regular monitoring of renal function, adjusting medications based on kidney status, and managing complications like anemia and electrolyte imbalances. In the presented vignette, the patient's hypercalcemia from calcium carbonate indicates the need for a non-calcium binder to control phosphate. The correct choice, switching calcium carbonate to sevelamer with meals, accurately reflects current guidelines for managing hyperphosphatemia in CKD stage 4, demonstrating the student's understanding of appropriate clinical interventions. A common distractor may suggest adding calcitriol first, which can worsen hypercalcemia, highlighting a frequent misconception. To improve understanding, students should focus on guidelines for CKD-MBD therapy, regularly review binder side effects, and practice selecting agents based on lab profiles.

Question 12

1. Hepatitis B vaccine series (correct answer)
2. Herpes zoster vaccine (recombinant)
3. Human papillomavirus vaccine
4. Measles, mumps, and rubella vaccine

Explanation: Patients with advanced CKD who are likely to require dialysis are at increased risk of acquiring hepatitis B infection. Furthermore, their immune response to vaccination is often blunted, and the response is better before the initiation of dialysis. Therefore, administering the hepatitis B vaccine series is a high priority in the pre-ESRD population. While other vaccines are important, the Hepatitis B series has unique urgency in this clinical context.

Question 13

1. Initiate a non-calcium phosphate binder like sevelamer.
2. Initiate a calcimimetic such as cinacalcet.
3. Initiate an active vitamin D analog like calcitriol.
4. Initiate nutritional vitamin D supplementation with ergocalciferol. (correct answer)

Explanation: This patient has secondary hyperparathyroidism and vitamin D deficiency. The initial step in management is to correct the nutritional vitamin D deficiency with ergocalciferol (D2) or cholecalciferol (D3). Repleting vitamin D stores can help lower PTH levels. Active vitamin D analogs like calcitriol are typically reserved for more severe hyperparathyroidism in later-stage CKD, especially in dialysis patients, and are used after nutritional vitamin D is replete. His phosphorus is only minimally elevated, not warranting a binder at this time.

Question 14

1. Add losartan to the lisinopril.
2. Add spironolactone.
3. Add finerenone. (correct answer)
4. Add hydralazine.

Explanation: For patients with diabetic kidney disease who have persistent albuminuria despite treatment with an ACE inhibitor or ARB and an SGLT2 inhibitor, adding a non-steroidal mineralocorticoid receptor antagonist (MRA) like finerenone is indicated. Finerenone has been shown in large clinical trials to reduce the risk of CKD progression and cardiovascular events in this population. Dual RAAS blockade (ACEi + ARB) is contraindicated. While spironolactone is also an MRA, finerenone has a better side-effect profile regarding hyperkalemia and has specific outcome data for this indication.

Question 15

1. Renoprotectin is a safe and effective treatment for all patients with chronic kidney disease.
2. The benefit of renoprotectin does not outweigh its risks because the p-value is greater than 0.001.
3. The study demonstrates that renoprotectin prevents the need for dialysis in patients with CKD.
4. Renoprotectin reduces the risk of the primary composite endpoint but increases the risk of hyperkalemia. (correct answer)

Explanation: The abstract shows a statistically significant reduction in the primary composite endpoint (HR 0.75, 95% CI does not cross 1.0, p=0.01). This indicates the drug is effective. However, it also shows a doubling of the rate of hyperkalemia. Therefore, the most accurate conclusion is that the drug reduces major adverse events but at the cost of an increased risk of hyperkalemia. The other options are inaccurate generalizations or misinterpretations of the statistical data.

Question 16

1. "Dialysis is the standard treatment, so we should schedule him for access placement right away."
2. "His advance directive is clear, so we are legally unable to offer him dialysis treatment."
3. "We can start with a trial of dialysis for a few weeks and stop if there's no improvement."
4. "Let's talk about your father's current condition and what your goals are for his care at this stage." (correct answer)

Explanation: When you encounter questions about end-of-life care decisions, focus on patient-centered communication and shared decision-making rather than making unilateral medical recommendations. These scenarios test your understanding of how to navigate complex ethical situations involving advance directives, family dynamics, and goals of care. The correct approach here is option D because it opens a dialogue to explore the family's understanding of the patient's condition, clarify his values and preferences, and discuss realistic treatment goals. This patient has multiple end-stage conditions (severe dementia, ESRD, advanced heart failure) that collectively suggest a very poor prognosis. Before making any treatment decisions, you need to understand what "life-prolonging procedures" and "terminal condition" meant to this patient when he wrote his directive. Option A is wrong because it bypasses the ethical complexity and ignores the advance directive entirely. Starting dialysis without exploring goals of care could violate the patient's wishes. Option B incorrectly suggests that advance directives create absolute legal barriers. While the directive provides guidance, it requires interpretation - does ESRD with multiple comorbidities constitute his envisioned "terminal condition"? Option C proposes a trial approach but still doesn't address the fundamental question of whether dialysis aligns with the patient's values and the family's goals for his care. For USMLE Step 3, remember that end-of-life scenarios prioritize communication and shared decision-making over immediate medical interventions. When advance directives are involved, your first step should always be exploring their meaning with the patient/family rather than making assumptions about what they permit or prohibit.

Question 17

1. Rapidly progressive glomerulonephritis
2. Acute interstitial nephritis due to atorvastatin
3. Prerenal azotemia from volume depletion (correct answer)
4. Postrenal obstruction not visible on ultrasound

Explanation: This patient presents with an acute decline in renal function superimposed on her chronic kidney disease. The BUN-to-creatinine ratio is high (80/2.5 = 32), which strongly suggests a prerenal cause. Her clinical history of nausea and poor oral intake supports volume depletion as the etiology. The bland urinalysis and normal ultrasound make intrinsic renal disease (like glomerulonephritis or interstitial nephritis) and obstruction less likely.

Question 18

1. Limit sodium intake to under 2 g daily (correct answer)
2. Increase protein intake to 1.8 g/kg daily
3. Increase potassium-rich foods to prevent cramps
4. Avoid all dietary fat to slow CKD progression

Explanation: This question tests chronic kidney disease management skills, specifically focusing on evidence-based dietary recommendations for CKD patients. Chronic kidney disease management involves regular monitoring of renal function, adjusting medications based on kidney status, and managing complications like anemia and electrolyte imbalances. In the presented vignette, the patient's proteinuria and stable electrolytes indicate the need for sodium restriction to control blood pressure and reduce progression. The correct choice, limiting sodium intake to under 2 g daily, accurately reflects current guidelines for managing CKD stage 3b, demonstrating the student's understanding of appropriate clinical interventions. A common distractor may suggest increasing protein intake, which can worsen proteinuria, highlighting a frequent misconception. To improve understanding, students should focus on nutritional guidelines for CKD, regularly review dietary impacts on renal function, and practice counseling patients on lifestyle modifications.

Question 19

1. Administer intravenous iron for functional iron deficiency (correct answer)
2. Increase epoetin dose without addressing iron stores
3. Transfuse packed red blood cells as first-line
4. Stop losartan to improve hemoglobin concentration

Explanation: This question tests chronic kidney disease management skills, specifically focusing on evidence-based treatment for anemia with functional iron deficiency in CKD patients. Chronic kidney disease management involves regular monitoring of renal function, adjusting medications based on kidney status, and managing complications like anemia and electrolyte imbalances. In the presented vignette, the patient's low transferrin saturation despite high ferritin indicates functional iron deficiency, requiring IV iron. The correct choice, administering intravenous iron for functional iron deficiency, accurately reflects current guidelines for managing anemia in CKD stage 4, demonstrating the student's understanding of appropriate clinical interventions. A common distractor may suggest transfusing RBCs first, which is not preferred due to risks, highlighting a frequent misconception. To improve understanding, students should focus on guidelines for CKD anemia, regularly review iron studies, and practice distinguishing absolute from functional deficiencies.

Question 20

1. Place a tunneled dialysis catheter once symptoms of uremia develop.
2. Refer to vascular surgery for evaluation for an arteriovenous fistula. (correct answer)
3. Wait until her eGFR is less than 10 mL/min/1.73m² to plan for dialysis access.
4. Initiate education for peritoneal dialysis as it is a superior option.

Explanation: For patients planning to start hemodialysis, placement of an arteriovenous (AV) fistula is the preferred access method due to lower rates of infection and thrombosis and better long-term patency compared to grafts or catheters. An AV fistula requires 3-6 months to mature. Therefore, referral to a vascular surgeon for evaluation and placement should occur well in advance of the need for dialysis, typically when the eGFR falls below 20-25 mL/min/1.73m².